[
  {
    "ts": null,
    "headline": "Pfizer Enters into Exclusive Licensing Agreement with 3SBio",
    "summary": "NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial effic",
    "url": "https://finnhub.io/api/news?id=106a4c378b2f85bb4dd8a9a30cd3c6dcea2ed12aea9a3c19675c8b6362e5c164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747699200,
      "headline": "Pfizer Enters into Exclusive Licensing Agreement with 3SBio",
      "id": 134609211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, May 20, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. SSGJ-707 has shown initial effic",
      "url": "https://finnhub.io/api/news?id=106a4c378b2f85bb4dd8a9a30cd3c6dcea2ed12aea9a3c19675c8b6362e5c164"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer",
    "summary": "Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer",
    "url": "https://finnhub.io/api/news?id=5a8fb0ef7eb882b85bf95d6ad5138677709123e2a8cfaaf79ef9cbdd7a213377",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747699080,
      "headline": "Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer",
      "id": 134615002,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Biotech Company 3SBio's Shares Surge After $6 Billion Licensing Deal With Pfizer",
      "url": "https://finnhub.io/api/news?id=5a8fb0ef7eb882b85bf95d6ad5138677709123e2a8cfaaf79ef9cbdd7a213377"
    }
  },
  {
    "ts": null,
    "headline": "Sunshine Guojian Says Co And Affiliates Have Granted Pfizer An Exclusive License On Commercialization Of Cancer Drug",
    "summary": "Sunshine Guojian PharmaceuticalShanghai Co Ltd: * SAYS CO AND AFFILIATES HAVE GRANTED PFIZER AN EXCLUSIVELICENSEON COMMERCIALIZATION OF CANCER DRUG Source textFurther...",
    "url": "https://finnhub.io/api/news?id=e2826f5b2ec6a18af9b3003c05dcd2e0954fee203647cf0d378aae99fb892408",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747686427,
      "headline": "Sunshine Guojian Says Co And Affiliates Have Granted Pfizer An Exclusive License On Commercialization Of Cancer Drug",
      "id": 134603893,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Sunshine Guojian PharmaceuticalShanghai Co Ltd: * SAYS CO AND AFFILIATES HAVE GRANTED PFIZER AN EXCLUSIVELICENSEON COMMERCIALIZATION OF CANCER DRUG Source textFurther...",
      "url": "https://finnhub.io/api/news?id=e2826f5b2ec6a18af9b3003c05dcd2e0954fee203647cf0d378aae99fb892408"
    }
  },
  {
    "ts": null,
    "headline": "3Sbio Enters Into License Agreement With Pfizer",
    "summary": "3SBio Inc: * ENTERING INTO LICENSE AGREEMENT FOR PD-1/VEGF BISPECIFICANTIBODY WITH PFIZER * POSSIBLE SUBSCRIPTION OF CERTAIN NUMBER OF NEW SHARES OFCOMPANYBY PFIZER ...",
    "url": "https://finnhub.io/api/news?id=09b114b99a6f0b386edb60fea302b65bd722a93237a15bdb305e19fe6d43638d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747681447,
      "headline": "3Sbio Enters Into License Agreement With Pfizer",
      "id": 134603805,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "3SBio Inc: * ENTERING INTO LICENSE AGREEMENT FOR PD-1/VEGF BISPECIFICANTIBODY WITH PFIZER * POSSIBLE SUBSCRIPTION OF CERTAIN NUMBER OF NEW SHARES OFCOMPANYBY PFIZER ...",
      "url": "https://finnhub.io/api/news?id=09b114b99a6f0b386edb60fea302b65bd722a93237a15bdb305e19fe6d43638d"
    }
  },
  {
    "ts": null,
    "headline": "Buy These 2 Beaten Down Stocks Now Before They Rally",
    "summary": "Read about why American Assets Trust & Alexandria Real Estate are top REIT stock picks for long-term dividends.",
    "url": "https://finnhub.io/api/news?id=28606007af3b222ef9836f53678eba17bc4623614d1f07bdb6d144e94fe266ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747659600,
      "headline": "Buy These 2 Beaten Down Stocks Now Before They Rally",
      "id": 134591955,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/456509341/image_456509341.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Read about why American Assets Trust & Alexandria Real Estate are top REIT stock picks for long-term dividends.",
      "url": "https://finnhub.io/api/news?id=28606007af3b222ef9836f53678eba17bc4623614d1f07bdb6d144e94fe266ab"
    }
  },
  {
    "ts": null,
    "headline": "PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?",
    "summary": "Both PFE and MRK have strong product and pipeline portfolios in oncology.",
    "url": "https://finnhub.io/api/news?id=a1bc083357ba4bf251163c258d3563119fbe46644b05f47813b4768b13d70ed5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747657740,
      "headline": "PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?",
      "id": 134601634,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Both PFE and MRK have strong product and pipeline portfolios in oncology.",
      "url": "https://finnhub.io/api/news?id=a1bc083357ba4bf251163c258d3563119fbe46644b05f47813b4768b13d70ed5"
    }
  },
  {
    "ts": null,
    "headline": "Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.",
    "summary": "Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.",
    "url": "https://finnhub.io/api/news?id=83c0761be056b5a1c569a650117defffe1e71d64b1947e4fcea3da5272465408",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747650600,
      "headline": "Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.",
      "id": 134586553,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.",
      "url": "https://finnhub.io/api/news?id=83c0761be056b5a1c569a650117defffe1e71d64b1947e4fcea3da5272465408"
    }
  },
  {
    "ts": null,
    "headline": "Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology",
    "summary": "Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for long-term investors.",
    "url": "https://finnhub.io/api/news?id=05aa8a7840eb5c9e7b8b4a0b27a438566e3fe935528a088d33341dc09ac70511",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747638225,
      "headline": "Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology",
      "id": 134576550,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/927016002/image_927016002.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Genmab's antibody platforms, growing royalties, and late-stage pipeline make it a top biotech stock for long-term investors.",
      "url": "https://finnhub.io/api/news?id=05aa8a7840eb5c9e7b8b4a0b27a438566e3fe935528a088d33341dc09ac70511"
    }
  },
  {
    "ts": null,
    "headline": "1 Profitable Stock on Our Watchlist and 2 to Turn Down",
    "summary": "A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
    "url": "https://finnhub.io/api/news?id=7eafd5378eaf6fda8c969bf81c1a92fef4a7c04909a2aaa6493d951d16be916f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747629636,
      "headline": "1 Profitable Stock on Our Watchlist and 2 to Turn Down",
      "id": 134577372,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
      "url": "https://finnhub.io/api/news?id=7eafd5378eaf6fda8c969bf81c1a92fef4a7c04909a2aaa6493d951d16be916f"
    }
  }
]